Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

79.58 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,878
Open 79.58
Bid (Size) 78.96 (5)
Ask (Size) 79.00 (9)
Prev. Close 79.58
Today's Range 79.58 - 79.58
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct

Performance

YTD
+16.35%
+16.35%
1 Month
-7.16%
-7.16%
3 Month
+3.62%
+3.62%
6 Month
+19.11%
+19.11%
1 Year
+20.10%
+20.10%

More News

Read More
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
From AstraZeneca
Via Business Wire
Is Summit Therapeutics Stock a Buy?
Via The Motley Fool
Week In Review: Zenas Raises $259 Million In IPO
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Top Stock Reports For Toyota, AstraZeneca & Chubb
Via Talk Markets
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
Via Benzinga
Exposures Product Safety
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Via Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
Via Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Via Benzinga
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
From AstraZeneca
Via Business Wire
FLUMIST approved for self-administration in the US
From AstraZeneca
Via Business Wire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Via The Motley Fool
Topics Stocks
Exposures US Equities
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
Via Benzinga
Exposures Product Safety
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
From AstraZeneca
Via Business Wire
5 Oversold Stocks to Buy Right Now
Via MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.